YHR2402
Phase 3Small molecule
YHR2402 is one of 12 small molecule programs targeting Acute bronchitis. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Acute Bronchitis
#DrugCompanyPhaseTrials
1Ceftin
PPhiladelphia Eye Associates
Approved
Azithromycin IV
PfizerPhase 3
Andrographolide Sulfonate
JJiangxi Qingfeng Pharmaceutical Co. Ltd.
Approved
Erdos
Daewoong Pharmaceutical Co. LTD.Approved
Bronpass Tab.
HHanlim Pharm. Co., Ltd.
Approved
YHR2402
YYuhan Corporation
Phase 3
HL301
HHanlim Pharm. Co., Ltd.
Phase 2
Placabo
AAllergopharma GmbH & Co. KG
Phase 2
Gantanol
CConrado Roberto Hoffmann Filho
Preclinical
Primsol
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YHR2402. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- YYuhan Corporation